DDAVP Drug Patent Profile

When do Ddavp patents expire, and what generic alternatives are available?

Ddavp is a drug marketed by J Molner and Ferring Pharms Inc and is included in three NDAs.

The generic ingredient in DDAVP is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ddavp

A generic version of DDAVP was approved as desmopressin acetate by MEITHEAL on October 15^th, 1997.

Summary for DDAVP

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	176
Drug Prices:	Drug price information for DDAVP
What excipients (inactive ingredients) are in DDAVP?	DDAVP excipients list
DailyMed Link:	DDAVP at DailyMed

See drug prices for DDAVP

Pharmacology for DDAVP

Drug Class	Factor VIII Activator Vasopressin Analog
Physiological Effect	Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration

US Patents and Regulatory Information for DDAVP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
J Molner	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938-001	Mar 30, 1984	AP	RX	Yes	Yes
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996		DISCN	Yes	No
Ferring Pharms Inc	DDAVP	desmopressin acetate	SPRAY, METERED;NASAL	017922-002	Feb 6, 1989		DISCN	Yes	No
J Molner	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938-002	Apr 25, 1995		DISCN	No	No
Ferring Pharms Inc	DDAVP	desmopressin acetate	SOLUTION;NASAL	017922-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-002	Sep 6, 1995	AB	RX	Yes	Yes

Expired US Patents for DDAVP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-001	Sep 6, 1995	5,500,413
Ferring Pharms Inc	DDAVP	desmopressin acetate	SPRAY, METERED;NASAL	017922-002	Feb 6, 1989	5,763,407
Ferring Pharms Inc	DDAVP	desmopressin acetate	SOLUTION;NASAL	017922-001	Approved Prior to Jan 1, 1982	3,497,491
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-002	Sep 6, 1995	7,022,340
J Molner	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938-001	Mar 30, 1984	3,497,491
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-001	Sep 6, 1995	5,763,407

International Patents for DDAVP

See the table below for patents covering DDAVP around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	281312
Belgium	703908
Switzerland	495957	Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids (Antidiuretic polypeptide)
Germany	1643273	ANTIDIURETISCH WIRKSAMES POLYPEPTID UND VERFAHREN ZU SEINER HERSTELLUNG
Denmark	134857
Spain	345047

Supplementary Protection Certificates for DDAVP

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2712622	122017000006	Germany		PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; AUTHORISATION NO/DATE: 94726.00.00 20160901; 94725.00.00 20160901; BE497271 20160504; BE497280 20160504
2712622	LUC00015	Luxembourg		PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
3225249	300983	Netherlands		PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
3225249	CA 2019 00023	Denmark		PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
3225249	2019C/520	Belgium		PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622	C02712622/01	Switzerland		PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018

DDAVP (desmopressin) Market Dynamics and Financial Trajectory (US and major ex-US markets)

Last updated: July 30, 2026

DDAVP (desmopressin acetate, nasal spray and tablets; also presented as DDAVP brand in multiple dosage forms depending on market) is a mature, revenue-stable endocrinology product with pricing and share shaped by generic penetration, formulary dynamics, and ongoing demand tied to central diabetes insipidus (DI) and nocturia indications. Financial trajectory is driven less by patent exclusivity and more by lifecycle management, route-of-administration mix (oral vs intranasal), supply continuity, and competitive intensity from authorized generics and unbranded generics. In the US, the brand’s long-term revenue has been constrained by generic entry in key formats, leaving any upside tied to remaining branded niches, payer coverage, and persistent use in pediatric and refractory patient subpopulations.

What is DDAVP’s current market position and revenue trend?

DDAVP sits in the desmopressin franchise, used across:

• Central diabetes insipidus (neurohypophyseal DI)
• Primary nocturnal enuresis (PNE) in pediatric populations (where approved in the relevant jurisdiction)
• Nocturia related to bladder outlet/overactive bladder phenotypes (jurisdiction and product-specific labeling dependent)
• Perioperative and diagnostic use cases in some settings (labeling varies)

Revenue trend characteristics for a mature desmopressin brand:

• Gradual decline after generic entry in major dosage forms, followed by stabilization where brand differentiation persists through supply, dosing convenience, and prescriber familiarity.
• Volatility risk tied to manufacturing capacity and regulatory enforcement events affecting intranasal products.
• Share shifts toward the most convenient and cheapest reimbursed option (often generic oral).
• Fragmented country-by-country economics due to different patent expiries, reimbursement structures, and import channels.

Bottom line for market positioning: DDAVP behaves like a “maintenance brand” within an endocrine portfolio, with growth capped by generic substitution unless market access barriers favor branded intranasal products or a brand remains the default in specific patient segments.

What market drivers most affect DDAVP demand?

Central diabetes insipidus: why it still matters commercially

Central DI is chronic and is managed long-term. That creates a recurring baseline demand, but it does not guarantee branded revenue because:

• Prescribers can switch between desmopressin formulations (spray vs tablets) when clinically appropriate.
• Payers often steer toward low-cost generics.

Key demand drivers:

• Lifetime therapy and dose titration for each patient
• Pediatric dependence on desmopressin for adherence and caregiver-administered dosing (depending on local formulation availability)
• Regional differences in guideline adoption and clinician preference for intranasal vs oral

Nocturia and nocturnal enuresis: reimbursement sensitivity

Nocturia and PNE are sensitive to:

• Payer step therapy and prior authorization requirements
• Restrictions on age, symptom frequency thresholds, and contraindications (e.g., hyponatremia risk)
• Duration-of-therapy limits or periodic reassessment

This keeps demand more “payer-managed” than in central DI, increasing substitution pressure.

Product form factor and adherence economics

Route-of-administration mix drives revenue more than incremental indication growth:

• Intranasal products often face more stringent manufacturing scrutiny and supply shocks, which can temporarily strengthen brand performance but can also destabilize availability.
• Oral tablets generally see higher generic penetration and lower brand resilience.

How does generic and authorized generic competition reshape DDAVP financials?

The generic substitution mechanism

DDAVP brand revenue is pressured by:

• Direct-to-market generic desmopressin acetate (intranasal and tablets depending on the jurisdiction and concentration)
• Authorized generics and branded generics (where the label remains “desmopressin” but price is compressed)
• Pharmacy switching under low copays and formulary tiering

The commercial effect:

• Faster share loss in retail markets where substitution is automatic or encouraged.
• Slower share loss in specialty-managed settings where dosing and monitoring are more controlled (especially for pediatric and sodium-sensitive patients).

Price erosion profile typical for mature generics

For mature oral/intranasal hormone analogs:

• Wholesale acquisition cost and contract pricing compress post-entry.
• Net price depends heavily on wholesaler and PBM rebates, which are harder to sustain for a brand after competition peaks.

What Orange Book and exclusivity facts govern DDAVP’s US financial trajectory?

DDAVP’s US branded trajectory has been mainly determined by (1) when specific product strengths/routes entered generic competition and (2) whether any later-listed formulation, method-of-use, or pediatric exclusivity maintained value. In practice, the operational driver is which specific NDCs remain brand-controlled versus generic-controlled, because DDAVP is not a single monolithic asset.

Featured snippet answer (business rule): DDAVP’s US financial trajectory is dictated by product-level exclusivity and NDC-level generic penetration, not by a single expiration date.

When did generic competition begin to cap DDAVP revenues?

For DDAVP, generic entry typically began years earlier than many contemporary biotech launch cycles, creating a long runway of brand erosion. The ongoing relevance for investors and litigators is:

• Whether any later-conceived patents (reformulations, dosing regimens, or device delivery) delayed certain NDCs
• Whether any litigation settlements or risk-based exclusivity blocks prevented immediate generic launches for specific dosage forms

Actionable commercial view: even if brand protection existed for a period, the market is now in a late lifecycle where incremental growth is constrained and revenue largely tracks patient continuity and prescriber routing of therapy.

What patent estate issues still matter for DDAVP economics?

Formulation and device patents can influence intranasal mix

Even when composition patents expire, later IP can affect:

• Delivery device design (spray mechanics, dose accuracy)
• Stability/packaging improvements
• Specific concentration strengths that align with pediatric dosing schedules

If any of these rights remain in a given jurisdiction, they can delay generic switching for particular NDCs and preserve a sliver of branded pricing power.

Method-of-use and pediatric regimen protection

Where method-of-use or dosing regimen patents exist, they can complicate “same-label” generic substitution if the generic must change dosing frequency or monitoring requirements. In practice, most generic challenges center on label carve-outs and paragraph IV certifications tied to Orange Book listings.

What regulatory pathway dynamics influence DDAVP market access?

DDAVP’s regulatory lifecycle is shaped by:

• Bioequivalence requirements for generics and formulation changes
• Risk management for hyponatremia (labeling, contraindications, and warnings)
• Pediatric dosing constraints that can affect PBM coverage policies and prescriber uptake of a given generic

Commercial linkage: regulatory labeling that highlights monitoring and patient selection can slow switching if prescribers trust brand-specific dosing guidance more than generic inserts.

Which companies compete with DDAVP and how does that affect pricing?

Competition is generally from:

• Multiple generic manufacturers supplying desmopressin acetate generics for intranasal and oral products
• Authorized generic programs (where brand originators or licensees structure a lower-priced branded supply chain)

Pricing impact pattern:

• Rapid downward adjustment at launch of new dosage forms
• Subsequent stabilization when supply stabilizes and rebate pressure equilibrates

In many markets, pricing becomes less about innovation and more about:

• Contracting with PBMs/large wholesalers
• Tender participation for public hospital systems
• Availability guarantees for pediatric formulations

How do settlement agreements and litigation outcomes affect DDAVP timelines?

For mature products like DDAVP, litigation outcomes influence:

• When specific generic entrants can launch (launch dates tied to settlement terms)
• Whether certain label indications or strengths are carved out
• Which NDCs are “delayed,” preserving branded revenue for longer than expected

Business-critical effect: the economic impact is usually concentrated in a handful of dosage strengths that remain brand-controlled longest.

What is the biosimilar or biologics risk for DDAVP?

DDAVP is a small-molecule/peptide hormone analog formulation, not a biologic. Biosimilar dynamics do not apply.

The relevant “substitution risk” is generic desmopressin substitution, not biosimilar competition.

How do formulation and delivery system patents affect switching risk?

Switching risk differs by route:

• Intranasal: device accuracy, spray consistency, and patient training issues can slow substitution, even when generics are available.
• Oral tablets: substitution is typically easier and more automatable for pharmacies, leading to faster price compression.

Net effect: DDAVP intranasal segments can hold value longer than oral segments in some formularies, but they remain exposed to availability shocks and generic price benchmarking.

What generic entry risks exist for DDAVP in key jurisdictions?

Generic entry risk is highest where:

• Patent and regulatory exclusivities are clearly expired for that exact strength/route
• Multiple generic manufacturers have established supply chains
• Local reimbursement favors lowest-cost alternatives

For business planning, the primary risk is not a “new competitor” emerging. It is ongoing incremental NDC switching as additional strengths become interchangeable and as tender cycles re-award supply.

How does DDAVP compare with other desmopressin branded products?

Across global markets, desmopressin competes within its own class:

• Some countries favor different branded desmopressin products by route or concentration
• Switching can occur between brand families if dosing equivalence is accepted by local prescribing practices

Commercial takeaway: DDAVP brand strength is often more “distribution and formulary placement” than “clinical superiority,” with differentiation centered on patient experience and supply continuity.

Financial trajectory: what metrics best track DDAVP performance?

For a mature endocrinology brand, the most decision-useful metrics are:

• Share by route (intranasal vs oral tablets)
• Prescription volume trends for each NDC/strength
• Average net price and contract price compression vs generic benchmarks
• Inventory and availability indicators (stockouts strongly affect Rx continuity)
• Payer mix (retail vs specialty-managed coverage) and formulary tier position

Investor-grade read-through: watch NDC-level displacement curves post generic entry, then track whether brand holds any “last mile” niche (pediatrics, intranasal adherence, stable monitoring programs).

Key takeaways

• DDAVP’s market is mature; financial trajectory is primarily a function of NDC-level generic penetration, route-of-administration mix, and formulary access rather than ongoing innovation.
• Central DI provides a recurring demand base, but it does not prevent price erosion because desmopressin generics are substitutable in most payer environments.
• Intranasal products can preserve value longer due to route-specific adherence and supply considerations, but they are exposed to availability shocks and device/label acceptance issues.
• Litigation and settlements matter mainly when they delay generic entry for specific strengths/routes, not as broad protections across the entire franchise.

FAQs

1) Which DDAVP dosage forms typically lose brand share first to generics?
Oral tablets usually see faster and deeper substitution, while intranasal products can retain brand presence longer depending on device acceptance and supply continuity.

2) Does hyponatremia risk affect DDAVP payer decisions and switching speed?
Yes. Increased monitoring requirements and contraindication screens can slow switching where prescriber workflows rely on brand-specific patient counseling or monitoring programs.

3) How do pediatric dosing schedules influence DDAVP commercial resilience?
Pediatric dosing practicality and caregiver administration can sustain demand for the most reliable available formulation, but generics can still capture share when coverage favors lowest cost.

4) Are there biosimilar threats to DDAVP?
No. DDAVP is not a biologic; the substitution threat is generic desmopressin acetate.

5) What is the main driver of DDAVP revenue volatility?
Supply and availability risk for intranasal products, plus changes in formulary tiering and contract pricing after generic launches.

References

1. APA style references are not provided because no specific source identifiers were included in the prompt.